|
Oral TXA group/control group
|
|---|
|
Studies (year)
|
Country
|
Cases
|
Ages (year)
|
Female gender (%)
|
Preoperative Hb (g/dL)
|
BMI (kg/m2)
|
Reference type
|
Preoperative diagnose
|
Preoperative thromboembolic events
|
Preoperative clotting disorder or anticoagulant therapy
|
QAS
|
|---|
|
Lee et al. (2017) [15]
|
China
|
94/95
|
70/68
|
67/69.55
|
13.6 ± 1.3/13.8 ± 1.2
|
27.7/28.4
|
RCT
|
N/A
|
None
|
None
|
6
|
|
Yuan et al. (2017) [14]
|
China
|
140/40
|
63.2/64.6
|
51.4/53.5
|
13.2 ± 0.8/13.2 ± 0.8
|
22.69/22.68
|
RCT
|
OA or RA
|
N/A
|
None
|
6
|
|
Perreault et al. (2017) [13]
|
USA
|
1049/866
|
66.1/66.2
|
62.4/58.2
|
14 ± 1.4/14 ± 1.4
|
N/A
|
RCS
|
N/A
|
None
|
N/A
|
6
|
|
Zohar et al. (2004) [21]
|
Israel
|
20/20
|
69/73
|
60/65
|
N/A
|
N/A
|
RCT
|
N/A
|
N/A
|
None
|
5
|
|
Alipour et al. (2013) [22]
|
Iran
|
27/26
|
68.6/63.11
|
59.3/56.7
|
N/A
|
28.9/29.3
|
RCT
|
OA or RA
|
None
|
None
|
6
|
|
Bradshaw et al. (2012) [20]
|
Australia
|
26/20
|
67.1/68.2
|
46.2/35
|
13.4 ± 2.5/13.8 ± 3
|
32.4/32.5
|
RCT
|
OA
|
None
|
None
|
6
|
-
TXA tranexamic acid, Hb hemoglobin, BMI body mass index, QAS quality assessment score, RCT randomized controlled trial, RCS retrospective cohort study, N/A not applicable, USA the United States of America, OA osteoarthritis, RA rheumatoid arthritis
